News blog
Silence Therapeutics
- BY: Andrew Hore |
- POSTED: 23/01/2012 |
- COMMENTS: Add yours
Richard Bernstein of investment company Eurovestech has increased his stake in Silence Therapeutics to more than 3%.
Bernstein owns 3.2% of Silence and through a CFD has an interest in a further 0.73%.
Shares in Silence rose 0.2p to 3.3p a share, which values Silence at £19m.
Silence is involved in the development of RNA interference (RNAi) therapeutics to treat serious diseases.
Download the latest AIM Journal from http://www.hubinvest.com/AIMPDFJanuary2012_28.pdf
© 2007 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- 2.4mNumber of messages posted on SocialGo networks
- $38mCost savings generated by ideas from WalMart staff over a two month period
- 19.4m
Number of people passing through Johannesburg Airport in 2007
- News Blog
- All micro news
Pursuit Dynamics
Steam-based technology developer Pursuit Dynamics lost four-fifths of its value after it said that Procter & Gamble will not be taking up an option to licence the company’s technology and that means that 2011-12 revenues will be much lower than expected.
Mercom Oil Sands
Oil sands properties developer Mercom Oil Sands plans to join Aim on 29 May.
Plus Markets Group
ICAP has acquired the Plus-SX business from Plus Markets Group but it is unlikely to be particularly interested in the Plus-quoted segment and its companies.
Sanderson Group
Enterprise software provider Sanderson Group is continuing to benefit from growth in multi-channel retailing.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|